April 27, 2024
Market Now
Alteogen clears phase 1 trial of Herceptin biosimilar in Canada
[DISCLOSURE] Alteogen (196170) said on Dec. 22 that its biosimilar of Roche’s breast cancer antibody Herceptin has cleared phase 1 clinical trials in Canada.
The biosimilar is scheduled to enter phase 3 clinical trials in 2017.
By Jung Min-kyung (mkj1105@heraldcorp.com)
The biosimilar is scheduled to enter phase 3 clinical trials in 2017.
By Jung Min-kyung (mkj1105@heraldcorp.com)
